Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol

• Published in: Biomedicine & pharmacotherapy 1997-01, Vol.51 (4), p.164-169
• Main Authors: Cimminiello, C, Vigorelli, P, Piliego, T, Soncini, M, Toschi, V, Arpaia, G, Perolini, S, Bonfardeci, C
• Format: Article
• Language: English
• Subjects: Aged; Analysis of Variance; Biological and medical sciences; Cholesterol, HDL - blood; Female; fibrinolysis; Fibrinolysis - drug effects; gemfibrozil; Gemfibrozil - pharmacology; Gemfibrozil - therapeutic use; General and cellular metabolism. Vitamins; HDL cholesterol; Humans; hypertriglyceridemia; Hypertriglyceridemia - complications; Hypertriglyceridemia - drug therapy; Hypertriglyceridemia - physiopathology; Hypolipidemic Agents - pharmacology; Hypolipidemic Agents - therapeutic use; Hypolipoproteinemias - complications; Hypolipoproteinemias - physiopathology; insulin; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/S0753-3322(97)85585-0

The combination of hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C) appears to be an excessively high risk factor for coronary artery disease (CAD). In the Helsinki study, both coronary events and mortality were decreased by gemfibrozil, especially in subjects with low HDL-C and high triglycerides (TG). On the other hand, it is known that high levels of TG can be associated with high levels of circulating plasminogen activator inhibitor (PAI), which is also a possible risk factor for CAD. The aim of the present study was to see: 1) whether the combination of low HDL-C and high TG is associated with a more impaired fibrinolytic response than in either isolated condition, and 2) whether gemfibrozil administration can improve fibrinolysis in patients with both high TG and low HDL-C. Twelve non-obese, non-diabetic subjects (eight men, four women; mean age 55 ± 13 yrs) with low HDL-C (< 35 mg/dL men; < 45 mg/dL women) and high TG (mean 253.6 ± 42.6 mg/dL) entered the study (Group A). Additionally fourteen comparable subjects with normal HDL-C were also investigated (Group B), plus 12 comparable subjects with isolated low HDL-C (Group C). Ten healthy people served as the control group. The following plasma fibrinolytic parameters were measured: tissue plasminogen activator antigen, PAI antigen and activity, euglobulin fibrinolytic activity (EFA) on fibrin plates, plasminogen and alpha-2-antiplasmin activities. All except the latter two values were also measured after venous occlusion (vo). In baseline conditions, patients in Groups A and B had higher EFA values before vo and higher PAI-1 antigen and alpha-2-antiplasmin levels after vo than those of controls or the subjects in Group C. The relationship between PAI antigen and PAI activity and TG was not confirmed in our population ( n = 48). We also saw no interference due to HDL-C, while there was a significant relationship between EFA before vo and both TG and cholesterol. After gemfibrozil treatment (600 mg bid for 12 weeks), the lipid profiles of subjects with high TG and low HDL-C were significantly improved. There was also a slight reduction of PAI activity after vo, while the PAI-1 antigen had decreased significantly from baseline after vo (56.3 ± 13 ng/mL before vo; 48.4 ± 21 ng/mL after vo; P = 0.04). The higher risk of CAD in patients with low HDL-C and high TG might be in part related to impairment of fibrinolysis, which occurs in patients with isolated high TG. The close relat